FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Imaging Diagnostic Systems, Inc., (OTCBB:IMDS - News) announced today that Shihab Muscat United (SMU) L.L.C. has been appointed as the exclusive distributor for the country of Oman. The company will market and service the CT Laser Mammography (CTLM®) system to the private and public sector of Oman.
IDSI exhibited at the Arab Health 2009 medical conference during which they met with many officials interested in marketing the CTLM system throughout different countries. In particular, IDSI discussed the marketing potential for the CTLM system for the country of Oman with a prominent company by the name of Shihab Muscat United L.L.C., which markets and services medical and dental products throughout Oman.
“One of the highlights of the CTLM system at the Arab Health conference was the discrete manner in which a woman is examined which is desirable in the Middle East due to the cultural customs. We hope to produce a long lasting relationship with SMU and introduce the CTLM system to the women of Oman,” stated Deborah O’Brien, Senior Vice President of Imaging Diagnostic Systems, Inc.
The quality of healthcare in Oman is generally high and equal to that in Western Europe. In addition, Oman recently announced plans to develop a healthcare city near Muscat with an investment of 300-400 million Rilas (Iranian currency). Managing Director Arvind Gaikwad of Shihab Muscat United L.L.C. will present the CT Laser Mammography system to the Ministry of Health officials of Oman and to the private imaging centers.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a patented new breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our corporate website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
